Handok will present a poster on the research and development results of the lung cancer treatment drug “HDBNJ-2812”’ at the American Association for Cancer Research (AACR 2024) held in San Diego, USA, from April 5th to 10th (local time).

This poster presentation includes the research design, synthesis, and evaluation of “HDBNJ-2812,” a next-generation EGFR mutation degradation lung cancer treatment drug that overcomes resistance induced by Osimertinib. “HDBNJ-2812” is an effective substance secured through collaboration between Handok and BNJ Biopharma. Handok has confirmed the possibility of developing a new drug for lung cancer treatment based on its proprietary drug development research infrastructure and BNJ Biopharma’s AI and advanced computer calculations.

The research results showed that “HDBNJ-2812” degrades various EGFR mutant proteins and inhibits cancer proliferation. Additionally, high drug stability and low cell toxicity potential was confirmed, indicating that it could be developed as a next-generation drug capable of overcoming resistance induced by Osimertinib.

Various EGFR inhibitor anticancer drugs developed for non-small cell lung cancer (NSCLC) have the limitation of resistance mutations due to the characteristics of low molecular inhibitors. In particular, Osimertinib, a third-generation inhibitor developed for NSCLC, can inhibit mutations such as L858R, Del19, and T790M, but it is ineffective against the C797S mutation. Osimertinib was expanded for insurance coverage as a first-line treatment for NSCLC earlier this year, but there is a need for the development of fourth-generation drugs that inhibit mutations resistant to Osimertinib.